Verbiage contained in a revised stay at home order issued by Colorado Gov. Jared Polis has led to the closure of some dietary supplement retailers in the state. It’s the second state after Nevada where such actions have been taken.
Health Canada has reiterated its stance that changes to product labels due to reclassification of species within the old Lactobacillus genus should occur within three years of changes to its monograph.
A group of trade associations has asked the IRS to allow the use of tax advantaged medical savings accounts to be used for the purchase of dietary supplements, a move that the group says could support consumers’ health as well as boost the economy.
Like many taking their work online during the coronavirus pandemic, antidoping officials who collect urine and blood samples from athletes are conducting their work over Zoom and FaceTime.
After years in the making, the taxonomic changes to the genus Lactobacillus have been published. The changes have significant impacts on many areas, from labeling to scientific publications and IP.
There is currently no cure for coronavirus, however, that hasn’t stopped companies from preying on consumers’ fears, as a new raft of FDA warning letters makes clear.
The sad news came this week of the death of a young girl who started a movement, one which has exposed again the built-in strains of how the dietary supplement market is regulated in the United States.
The US Food and Drug Administration has issued an additional six warning letters in recent days on coronavirus claims. The letters coincide with an industry coalition raising a red flag on the growing flood of such claims on dietary supplement-type products.
A coalition of dietary supplement industry trade associations have come out in support of FDA actions against fraudulent coronavirus treatment claims and have urged retailers to not stock products with such claims on their labels.
A wide ranging recall of products made by a New York-based contract manufacturer holds lessons supplement firms can use to avoid similar problems in the future, experts say.
The US Food and Drug Administration has issued another warning letter on COVID-19 claims. This one was issued to a Nevada company marketing CBD products.
Industry experts have slammed statements made in a recent JAMA Viewpoint that called for probiotics to be regulated to the same standard as drugs, and decried the “paucity of high-quality data supporting the value of probiotics”.
If only social distancing could stop the spread of misinformation. A prominent natural products chemist shares four steps on differentiating the real from the fake.
